ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (HBV). The Company is developing targeted antiviral therapies with two drug candidates in clinical studies. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or VZV. Its FV-100, which is in Phase III trials, is being developed for the treatment of herpes zoster, or shingles, and shingle pain. The Company is also developing CMX157, a highly potent analog of the antiviral drug tenofovir DF (Viread). Its CMX157 is a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. It has completed a Phase I clinical trial.
